Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Kathy M. Tran, Syed M. Kazmi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Stefan Faderl, MD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD

Blood (2012) 120 (21): 2592.

https://doi.org/10.1182/blood.V120.21.2592.2592

Published: 2012

Journal Articles

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Young Kwang Chae, MD, MPH, Long Xuan Trinh, Michael J. Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 2904.

https://doi.org/10.1182/blood.V120.21.2904.2904

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Nathalie Y Rosin, PhD, Stefan Koehrer, MD, Ekaterina Kim, MS, Susan O'Brien, M.D., William G. Wierda, MD, Ph.D., Deborah A. Thomas, MD, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Brian J. Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3534.

https://doi.org/10.1182/blood.V120.21.3534.3534

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Aziz Nazha, Hagop M. Kantarjian, MD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Zeev Estrov, MD, PhD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3587.

https://doi.org/10.1182/blood.V120.21.3587.3587

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, PhD, Gautam Borthakur, M.D., Susan M. O'Brien, MD, Tapan M. Kadia, M.D., Marina Konopleva, MD, PhD, Naval Daver, MD, Mark Brandt, BS, Heather Schroeder, RN, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3851.

https://doi.org/10.1182/blood.V120.21.3851.3851

Published: 2012

Journal Articles

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Rozovski Uri, MD, David Harris, Ping Li, PhD, Zhiming Liu, Srdana Grgurevic, Susan Lerner, MS, Matthew Martinez, William G. Wierda, MD, Ph.D., Michael Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 3910.

https://doi.org/10.1182/blood.V120.21.3910.3910

Published: 2012

Journal Articles

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Farhad Ravandi, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Charles Asa Koller, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Elizabeth M Burton, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 3617.

https://doi.org/10.1182/blood.V120.21.3617.3617

Published: 2012

Journal Articles

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Marina Konopleva, MD, PhD, Jan A. Burger, MD, PhD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Elias J. Jabbour, MD, Stefan Faderl, MD, Maria Diaz-Pines-Mateo, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Gautam Borthakur, M.D.

Blood (2012) 120 (21): 3619.

https://doi.org/10.1182/blood.V120.21.3619.3619

Published: 2012

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 43.

https://doi.org/10.1182/blood.V120.21.43.43

Published: 2012

Journal Articles

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Maro Ohanian, DO, Mona Lisa Alattar, MD, Zeev Estrov, MD, PhD, Alfonso Quintas-Cardama, MD, John T Manning, MD, Farhad Ravandi, MD, Lynne V. Abruzzo, MD, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1463.

https://doi.org/10.1182/blood.V120.21.1463.1463

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Ekaterina Kim, MS, Stefan Koehrer, MD, Nathalie Y Rosin, PhD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Steven M. Kornblau, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Zeev Estrov, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2569.

https://doi.org/10.1182/blood.V120.21.2569.2569

Published: 2012

NARROW

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only